Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Great. Good morning, everybody, again. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Pleased to have Genmab with me for the next session.
Just quickly before we get started, I need to read a disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales representative.
So very pleased to have Jan van de Winkel, who's the CEO of Genmab; and Anthony Pagano, who is the CFO with me today.
And Jan, I'm going to turn it over to you for some opening comments, and then we'll get into Q&A.
- /
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |